Anaphore raises $25 million for atrimer development
This article was originally published in Scrip
Anaphore has secured $25 million to advance the development of atrimers for immune-mediated diseases and cancer. Using its TrimerX technology platform, Anaphore develops atrimers by engineering a fully human serum protein that is secreted as a trimeric structure. The company said that the proceeds will fund its operations for around two years, perhaps longer if it signs partnering deals. The series A round was led by 5AM Ventures, Versant Ventures and Apposite Capital.